4.6 Review

Progress on the Prevention and Treatment of Hantavirus Disease

Journal

VIRUSES-BASEL
Volume 11, Issue 7, Pages -

Publisher

MDPI
DOI: 10.3390/v11070610

Keywords

hantavirus; hemorrhagic fever with renal syndrome; hantavirus pulmonary syndrome; vaccine; antiviral

Categories

Funding

  1. National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01AI32313]

Ask authors/readers for more resources

Hantaviruses, members of the order Bunyavirales, family Hantaviridae, have a world-wide distribution and are responsible for greater than 150,000 cases of disease per year. The spectrum of disease associated with hantavirus infection include hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS) also known as hantavirus cardiopulmonary syndrome (HCPS). There are currently no FDA-approved vaccines or treatments for these hantavirus diseases. This review provides a summary of the status of vaccine and antiviral treatment efforts including those tested in animal models or human clinical trials.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available